IL2 and neoplasm: To evaluate the effects of L19-IL2 in combination with standard therapy (FOLFOX) on tumor volume and survival rates of PDAC models with different immunogenic potential, C57BL/6J mice (RRID:IMSR_JAX:0006649) were orthotopically injected with KPC06 (Low immunogenic model) and KPC12 (Non immunogenic model).